The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended A trucker in his late 70s who can't ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

CVS Health opts for Wegovy and Saxenda on its formulary; Zepbound excluded. Millions affected as coverage choices impact cost and access to obesity drugs.

CVS Health recently chose Novo Nordisk's weight-loss drug Wegovy as a preferred drug on its formulary over Zepbound. Roche teamed up with Zealand Pharma, which has a promising weight-loss drug in ...

After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...